Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$516.22 USD

516.22
270,817

+8.80 (1.73%)

Updated Nov 5, 2024 10:23 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here's How

by Zacks Equity Research

PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.

Here's Why You Should Retain Catalent (CTLT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment

by Zacks Equity Research

Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.

Intuitive Surgical, Inc. (ISRG) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) closed at $1,039.01 in the latest trading session, marking a +1.09% move from the prior day.

Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients

by Zacks Equity Research

Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.

Here's Why You Should Retain CONMED (CNMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.

NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics

by Zacks Equity Research

NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.

Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ISRG) Outperforming Other Medical Stocks This Year?

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Reasons to Hold on to AMN Healthcare (AMN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Stryker (SYK) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.

TransMedics (TMDX) Receives FDA Nod for OCS Heart System

by Zacks Equity Research

TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.

Urmimala Biswas headshot

3 MedTech Sectors Benefiting Despite COVID-19 Resurgence

by Urmimala Biswas

Here we discuss three major subsectors of MedTech and some of their constituent stocks for which COVID-19 has opened up enormous growth prospects.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.

Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

by Zacks Equity Research

Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

by Zacks Equity Research

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Here's Why You Should Add STERIS (STE) to Your Portfolio Now

by Zacks Equity Research

STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.

Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic

by Zacks Equity Research

Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.

Thermo Fisher (TMO) Gains Government Contract for Pipette Tip

by Zacks Equity Research

Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.

Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) closed at $1,071.53 in the latest trading session, marking a +0.83% move from the prior day.

What Makes Intuitive Surgical, Inc. (ISRG) a New Strong Buy Stock

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials

by Zacks Equity Research

Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.

BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency

by Zacks Equity Research

BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.